UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                  FORM 10-QSB/A
                                (Amendment No. 1)


              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                      For Quarter Ended September 30, 2003

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                   For the transition period from ____ to ____

                         Commission file number: 0-25238

                           NATURAL HEALTH TRENDS CORP.
        (Exact Name of Small Business Issuer as Specified in its Charter)

                   Florida                              59-2705336
        State or other jurisdiction of               (I.R.S. Employer
         incorporation or organization              Identification No.)

                               12901 Hutton Drive
                               Dallas, Texas 75234
               (Address of Principal Executive Office) (Zip Code)

                                 (972) 241-4080
                 (Issuer's telephone number including area code)

       Indicate by check mark whether the issuer (1) has filed all reports
     required to be filed by Section 13 or 15(d) of the Securities Exchange
     Act of 1934 during the preceding 12 months and (2) has been subject to
                 such filing requirements for the past 90 days.

                 Yes [X]                                No [ ]

         The number of shares of issuer's Common Stock, $.001 par value,
           outstanding as of November 19, 2003 were 4,656,408 shares.



                           NATURAL HEALTH TRENDS CORP.

                                  Form 10-QSB/A

                      For Quarter Ended September 30, 2003


Explanatory Note:
----------------
The purpose of this amendment is to amend Part I, Item 2 - Management's
Discussion and Analysis and Part I, Item 1 -Financial Statements for the
restatements identified in note 2 to the consolidated financial statements and
to give effect to the 1 for 100 reverse stock split in March 2003. All other
items remain unchanged from the original filing.

During the quarters ended September 30 and December 31, 2003, the Company
re-evaluated its financial statements for the years ended December 31, 2002 and
2001, the quarterly periods included in such years and the quarterly periods
ended March 31, June 30 and September 30, 2003. As a result of such review, the
Company determined that it inadvertently applied the incorrect accounting
treatment with respect to the following items:

         (i)      revenue recognition with respect to administrative enrollment
                  fees;
         (ii)     revenue cut-off between 2002 and 2003;
         (iii)    accounts receivable reconciliation to supporting documents;
         (iv)     reserves established for product returns and refunds;
         (v)      the gain recorded in connection with the sale of a subsidiary
                  in 2001; and
         (vi)     income tax provisions.

Consequently, the Company is amending and restating its financial statements for
each quarter in 2001, 2002 and 2003 as well as the Form 10-KSB for the years
ended December 31, 2001 and 2002.



                           NATURAL HEALTH TRENDS CORP.

                                   FORM 10-QSB

                      For Quarter Ended September 30, 2003


                                      INDEX



                                                                           Page
                                                                          Number
PART I - FINANCIAL INFORMATION

  Item 1.  Financial Statements (unaudited)

           Consolidated Balance Sheet as of September 30, 2003                1

           Consolidated Statements of Operations
           for the three and nine months ended September 30, 2003 and 2002    2

           Consolidated Statements of Comprehensive Income
           for the three and nine months ended September 30, 2003 and 2002    3

           Consolidated Statements of Cash Flows
           for the nine months ended September 30, 2003 and 2002              4

           Notes to Consolidated Financial Statements                         5

  Item 2.  Management's Discussion and Analysis or Plan of Operations        10

  Item 3.  Controls and Procedures                                           13


PART II - OTHER INFORMATION

  Item 1.  Legal Proceedings                                                 14

  Item 2.  Changes in Securities and Use of Proceeds                         14

  Item 3.  Defaults Upon Senior Securities                                   14

  Item 4.  Submission of Matters to a Vote of Security Holders               14

  Item 5.  Other Information                                                 14

  Item 6.  Exhibits and Reports on Form 8-K                                  14

Signature                                                                    15

Certifications                                                               16



                           NATURAL HEALTH TRENDS CORP.

                           CONSOLIDATED BALANCE SHEET

                                   (UNAUDITED)

                                                                   September 30,
                                                                       2003
                                                                    As Restated
                                                                   ------------

                                     ASSETS
Current Assets:
       Cash                                                        $  4,086,437
       Accounts receivable                                            1,082,887
       Inventories                                                    4,102,266
       Prepaid expenses and other current assets                        769,734
       Restricted cash                                                1,179,728
                                                                   ------------
                   Total Current Assets                              11,221,052


       Property and equipment, net                                      860,611
       Deposits and other assets                                        928,658
       Goodwill                                                         207,765
       Database                                                         792,581
       Website                                                           22,167
                                                                   ------------
                   Total Assets                                    $ 14,032,834
                                                                   ============

                      LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
       Accounts payable                                            $  2,310,114
       Accrued expenses                                                 952,918
       Accrued associate commissions                                  1,544,908
       Notes payable                                                    275,051
       Current portion of long term debt                                 90,147
       Income tax payable                                             1,710,322
       Deferred revenue                                               2,048,837
       Other current liabilities                                        506,607
                                                                   ------------
                   Total Current Liabilities                          9,438,904
                                                                   ------------

    Long term debt                                                       39,864
                                                                   ------------
              Total Liabilities                                       9,478,768


Minority interest                                                       472,090

Stockholders' Equity:
       Preferred stock ($1,000 par value; authorized
       1,500,000 shares)                                                     --
       Common stock ($.001 par value; authorized
       500,000,000 shares; issued and outstanding 4,656,408
       shares)                                                            4,656
       Additional paid in capital                                    34,201,498
       Accumulated deficit                                          (30,171,660)
       Accumulated other comprehensive income                            47,482
                                                                   ------------
                   Total Stockholders' Equity                         4,081,976
                                                                   ------------


                Total Liabilities and Stockholders' Equity         $ 14,032,834
                                                                   ============

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       1



                           NATURAL HEALTH TRENDS CORP.

                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                   (UNAUDITED)


                                 Three Months Ended              Nine Months Ended
                                    September 30,                   September 30,
                            ----------------------------    ----------------------------
                                2003            2002            2003            2002
                             As Restated     As Restated     As Restated     As Restated
                            ------------    ------------    ------------    ------------
                                                                
Net sales                   $ 16,739,765    $ 10,840,365    $ 39,964,167    $ 24,555,530
Cost of sales                  3,671,035       1,995,547       7,449,725       4,415,042
                            ------------    ------------    ------------    ------------

Gross profit                  13,068,730       8,844,818      32,514,442      20,140,488

Associate commissions          6,988,233       4,665,502      16,498,279      12,412,739
Selling, general and
administrative expenses        4,132,874       2,878,838      10,982,703       7,216,289
                            ------------    ------------    ------------    ------------

Operating income               1,947,623       1,300,478       5,033,460         511,460


Minority interest in             (22,112)        (35,161)        (45,343)        (95,539)
subsidiary
Gain (loss) on foreign
currency                         (87,754)         45,113         (99,246)        (33,758)
Other income, net                (26,911)          5,222         (37,715)        (71,247)
Interest expense, net            (34,546)        (11,729)        (54,722)        (44,338)
                            ------------    ------------    ------------    ------------

Net income before taxes        1,776,300       1,303,923       4,796,434         266,578

Income tax expense               500,000              --       1,200,322              --
                            ------------    ------------    ------------    ------------

Net income                     1,276,300       1,303,923       3,596,112         266,578

Preferred stock dividends             --          19,313             810          60,773
                            ------------    ------------    ------------    ------------

Net income to common
stockholders                $  1,276,300    $  1,284,610    $  3,595,302    $    205,805
                            ============    ============    ============    ============

Basic income per
common share                $       0.27    $       0.42    $       0.78    $       0.07
                            ============    ============    ============    ============

Basic weighted common
shares used                    4,656,409       3,049,246       4,626,150       2,897,142
                            ============    ============    ============    ============


Diluted income per
common share                $       0.22    $       0.42    $       0.63    $       0.07
                            ============    ============    ============    ============

Diluted weighted
common shares used             5,820,570       3,058,679       5,662,703       2,906,576
                            ============    ============    ============    ============


              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       2


                           NATURAL HEALTH TRENDS CORP.

                 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

                                   (UNAUDITED)


                                 Three Months Ended            Nine Months Ended
                                    September 30,                 September 30,
                            ---------------------------   ---------------------------
                                2003           2002           2003           2002
                             As Restated    As Restated    As Restated    As Restated
                            ------------   ------------   ------------   ------------
                                                             
Net income                  $  1,276,300   $  1,303,923   $  3,596,112   $    266,578

Other comprehensive
income, net of tax:
  Foreign currency
  translation adjustments         41,611         96,328         57,048        155,985
                            ------------   ------------   ------------   ------------

Comprehensive income        $  1,317,911   $  1,400,251   $  3,653,160   $    422,563
                            ============   ============   ============   ============


              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       3



                           NATURAL HEALTH TRENDS CORP.

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (UNAUDITED)


                                                        Nine Months Ended
                                                           September 30,
                                                   ----------------------------
                                                       2003            2002
                                                    As Restated     As Restated
                                                   ------------    ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                         $  3,596,112    $    266,578
                                                   ------------    ------------

Adjustments to reconcile net income to net
cash provided by operating activities:

  Depreciation and amortization                         467,201         367,296
  Common stock issued for services and penalties         50,261           5,350
  Minority interest of subsidiary                        45,343          95,539

Changes in operating assets and liabilities:
  Accounts receivable                                  (563,135)       (339,411)
  Inventories                                          (948,642)       (962,228)
  Prepaid expenses and other current assets             848,916        (110,598)
  Deposits and other assets                            (597,052)       (469,174)
  Accounts payable and accrued expenses                (594,526)      3,760,988
  Income tax payable                                  1,200,322              --
  Deferred revenue                                   (1,450,555)      1,540,315
  Other current liabilities                            (146,437)        323,015
                                                   ------------    ------------
     Total Adjustments                               (1,688,304)      4,211,092
                                                   ------------    ------------
     NET CASH PROVIDED BY OPERATING ACTIVITIES        1,907,808       4,477,670
                                                   ------------    ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Capital expenditures                                 (449,392)       (399,329)
  Database purchase                                    (162,581)             --
  Increase in restricted cash                          (851,843)       (147,918)
                                                   ------------    ------------
     NET CASH USED IN INVESTING ACTIVITIES           (1,463,816)       (547,247)
                                                   ------------    ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Investments by minority interest owner                     --         135,714
  Proceeds from notes payable and long-term debt             --          75,000
  Payments of notes payable and long-term debt         (278,548)       (197,454)
                                                   ------------    ------------
     NET CASH (USED IN) PROVIDED BY
     FINANCING ACTIVITIES                              (278,548)         13,260
                                                   ------------    ------------

  Effect of exchange rate                                57,047         155,985

NET INCREASE IN CASH                                    222,491       4,099,668

CASH, BEGINNING OF PERIOD                             3,863,946         324,315
                                                   ------------    ------------

CASH, END OF PERIOD                                $  4,086,437    $  4,423,983
                                                   ============    ============

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       4


                           NATURAL HEALTH TRENDS CORP.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                      NINE MONTHS ENDED SEPTEMBER 30, 2003

                                   (UNAUDITED)


1.  Basis of Presentation

    We are Natural Health Trends Corp. ("NHTC"), an international direct-selling
    company. We operate through our subsidiaries that distribute products to
    promote health, wellness and vitality. Lexxus International, Inc., our
    majority-owned subsidiary and other Lexxus subsidiaries (collectively,
    "Lexxus"), sell certain cosmetic products as well as "quality of life"
    products. eKaire.com, Inc., our wholly-owned subsidiary ("eKaire"),
    distributes nutritional supplements aimed at general health and wellness.

    The accompanying unaudited financial statements of Natural Health Trends
    Corp. and its subsidiaries (the "Company") have been prepared in accordance
    with accounting principles generally accepted in the USA for interim
    financial information and with instructions to Form 10-QSB and Article 10 of
    Regulation S-B. Accordingly, they do not include all of the information and
    footnotes required by accounting principles generally accepted in the USA
    for complete financial statements. In the opinion of management, all
    adjustments considered necessary for a fair presentation (consisting of
    normal recurring accruals) of financial position and results of operations
    for the interim periods have been presented. Operating results for the three
    and nine months ended September 30, 2003 are not necessarily indicative of
    the results that may be expected for the year ending December 31, 2003, or
    any other interim period, and the Company makes no representation related
    thereto. For further information, refer to the consolidated financial
    statements and footnotes thereto included in the Company's Annual Report on
    Form 10-KSB for the year ended December 31, 2002.

2.  Restatement of Previously Issued Financial Statements

    During the quarters ended September 30 and December 31, 2003, the Company
    re-evaluated its financial statements for the years ended December 31, 2002
    and 2001, the quarterly period included such years and the quarterly periods
    ended March 31, June 30 and September 30, 2003. As a result of such review,
    the Company determined that it inadvertently applied the incorrect
    accounting treatment with respect to the following items:

    (i)   revenue recognition with respect to administrative enrollment fees;
    (ii)  revenue cut-off between 2002 and 2003;
    (iii) accounts receivable reconciliation to supporting documents;
    (iv)  reserves established for product returns and refunds;
    (v)   the gain recorded in connection with the sale of a subsidiary in 2001;
          and
    (vi)  income tax provisions.

    Consequently, the Company is amending and restating its financial statements
    for each quarter in 2001, 2002 and 2003 as well as the Form 10-KSB for the
    years ended December 31, 2001 and 2002.

    In connection with the engagement of a new independent accounting firm and
    the review of the Company's financial statements, the Company has revised
    its accounting treatment for administrative enrollment fees received from
    distributors in accordance with the principles contained in Staff Accounting
    Bulletin No. 101, "Revenue Recognition in Financial Statements", ("SAB 101")
    and related guidance. The Company determined that under SAB 101 such fees
    actually received and recorded as current sales in prior quarters should
    have been deferred and recognized as revenue on a straight-line basis over
    the twelve-month term of the membership. The restatement resulted in net
    sales for the three and nine-month periods ended September 30, 2003 being
    decreased by approximately $83,000 and being increased by $483,000,

                                       5


    respectively. The restatement resulted in net sales for the three and
    nine-month periods ended September 30, 2002 being decreased by approximately
    $156,000 and $1,537,000, respectively. The restatement in net sales resulted
    in a corresponding adjustment to cost of sales for direct costs paid to a
    third party associated with the administrative enrollment fees received from
    distributors. Compared to amounts previously reported, the restatement
    decreased cost of sales by approximately $29,000 and increased by $82,000
    for the three and nine-month periods ended September 30, 2003, respectively.
    Compared to amounts previously reported, the restatement decreased cost of
    sales by approximately $115,000 and $325,000 for the three and nine-month
    periods ended September 30, 2002, respectively.

    In addition, the Company and its new independent accounting firm reviewed
    revenue cut-off as of the beginning of 2003. It was noted that approximately
    $1,008,000 of sales originally recorded in 2002 were not actually shipped
    until early 2003. The restatement resulted in net sales for the year ended
    December 31, 2002 being decreased by $1,008,000 and net sales for the year
    ended December 31, 2003 being increased by the same amount. The restatement
    also resulted in distributor commissions for the year ended December 31,
    2002 being decreased by $459,000 and distributor commissions for the year
    ended December 31, 2003 being increased by the same amount.

    Also in connection with its review, the Company determined that its accounts
    receivable as of March 31 and June 30, 2003 did not reconcile in total to
    supporting details for such transactions. There was no impact of this
    restatement for the three months ended September 30, 2003. The restatement
    resulted in net sales being decreased $400,000 for the nine months ended
    September 30, 2003.

    The Company had not recorded a reserve for distributor returns and refunds
    as of September 30, 2003 and for prior periods. Based upon an analysis of
    the Company's historical returns and refund trends by country, it was
    determined that a reserve for returns and refunds for prior periods were
    required and should be recorded. The restatement resulted in net sales for
    the three and nine-month periods ended September 30, 2003 being increased by
    approximately $25,000 and $75,000, respectively, with corresponding
    adjustments to cost of sales for the estimated cost of products returned.
    The restatement resulted in net sales for the three and nine-month periods
    ended September 30, 2002 being decreased by approximately $88,000 and
    $263,000, respectively, with corresponding adjustments to cost of sales for
    the estimated cost of products returned.

    As previously disclosed in the Company's 2001 and 2002 Form 10-KSB, the
    Company sold in 2001 all of the outstanding common stock in Kaire
    Nutraceuticals, Inc. ("Kaire"), a Delaware corporation and wholly-owned
    subsidiary, to an unrelated third party. The gain on the sale of Kaire of
    approximately $3.1 million was previously deferred. The Company subsequently
    recognized into income approximately $1.9 million from the transaction over
    the period from Q4 2001 through Q2 2003. Based upon a review of the
    transaction, the Company now believes the gain on sale of Kaire should have
    been recognized only in 2001 and 2002. The restatement resulted in
    extraordinary gain due to forgiveness of debt for the three and nine months
    ended September 30, 2002 being decreased by $200,000 and $600,000,
    respectively. There is no impact of this restatement for the three or nine
    months ended September 30, 2003.

    The Company disclosed in its 2002 Form 10-KSB that it had a net operating
    loss carry forward at December 31, 2002 of approximately $6,000,000, subject
    to certain limitations. Consequently, the Company made no provision for
    income taxes for any period in either 2001 or 2002. Upon further review, it
    has been determined that the available net operating loss is not expected to
    be sufficient to offset all of the taxable income in 2002 and 2003. There
    is, however, no impact of this restatement for the three or nine months
    ended September 30, 2002. The impact of this restatement was $370,000 for
    the nine months ended September 30, 2003 which was recorded in the quarter
    ended March 31, 2003.

    The following table presents amounts from operations as previously reported
    and as restated (in thousands, except for per share data):

                                       6




                                              Three Months Ended             Nine Months Ended
                                              September 30, 2003             September 30, 2003
                                          ---------------------------   ---------------------------
                                               As             As             As             As
                                           Previously      Restated      Previously      Restated
                                            Reported                      Reported
                                          ------------   ------------   ------------   ------------
                                                                           
    Net sales                             $     16,740   $     16,740   $     39,356   $     39,964

    Cost of sales                                3,671          3,671          7,450          7,450
                                          ------------   ------------   ------------   ------------

    Gross profit                                13,069         13,069         31,906         32,514

    Operating expenses                          11,121         11,121         27,022         27,481
                                          ------------   ------------   ------------   ------------

    Operating income                             1,948          1,948          4,884          5,033
    Interest expense, other income,
    loss on foreign exchange and gain
    on discontinued operations                     171            171            237            237
                                          ------------   ------------   ------------   ------------

    Net income                                   1,776          1,776          4,647          4,796

    Income tax expense                             500            500          1,200          1,200

    Net income                                   1,276          1,276          3,447          3,596

    Preferred stock dividends                       --             --              1              1
                                          ------------   ------------   ------------   ------------
    Net income available to common
    stockholders                          $      1,276   $      1,276   $      3,446   $      3,595
                                          ============   ============   ============   ============


    Basic income per share                $       0.27   $       0.27   $       0.75   $       0.78
                                          ============   ============   ============   ============
    Basic weighted common shares used            4,656          4,656          4,590          4,626
                                          ============   ============   ============   ============

    Diluted income per share              $       0.22   $       0.22   $       0.61   $       0.63
                                          ============   ============   ============   ============
    Diluted weighted common shares used          5,752          5,821          5,685          5,663
                                          ============   ============   ============   ============


    Basic and Diluted Income per share:

    The adjustments in net sales and cost of sales, operating expenses, other
    income and income taxes resulted in a net increase in net income available
    to stockholders of approximately $0 and $149,000 over the amounts previously
    reported for the three and nine months ended September 30, 2003,
    respectively. Restated basic and diluted income per share did not change for
    the three months ended September 30, 2003. The basic and diluted income per
    share increased $0.03 and $0.02 for the nine months ended September 30,
    2003, respectively. The weighted common shares have been recalculated with
    the treasury stock method utilizing the average stock price for the period
    versus the closing stock price.

    The following table presents amounts from operations as previously reported
    and as restated (in thousands, except for per share data):

                                       7




                                               Three Months Ended             Nine Months Ended
                                               September 30, 2002             September 30, 2002
                                           ---------------------------   ---------------------------
                                                As             As             As             As
                                            Previously      Restated      Previously      Restated
                                             Reported                      Reported
                                           ------------   ------------   ------------   ------------
                                                                            
    Net sales                              $     11,084   $     10,840   $     26,355   $     24,555

    Cost of sales                                 2,128          1,995          4,793          4,415
                                           ------------   ------------   ------------   ------------

    Gross profit                                  8,956          8,845         21,562         20,140

    Operating expenses                            7,544          7,544         19,629         19,629
                                           ------------   ------------   ------------   ------------

    Operating income                              1,412          1,301          1,933            511
    Interest expense, other income,
    loss on foreign exchange and gain
    on discontinued operations                      203              3            356           (244)
                                           ------------   ------------   ------------   ------------

    Net income                                    1,615          1,304          2,289            267

    Preferred stock dividends                        19             19             61             61
                                           ------------   ------------   ------------   ------------
    Net income available to common
    stockholders                           $      1,596   $      1,285   $      2,228   $        206
                                           ============   ============   ============   ============


    Basic income per share                 $       0.52   $       0.42   $       0.77   $       0.07
                                           ============   ============   ============   ============
    Basic weighted common share used              3,049          3,049          2,897          2,897
                                           ============   ============   ============   ============

    Diluted income per share               $       0.52   $       0.42   $       0.77   $       0.07
                                           ============   ============   ============   ============
    Diluted weighted commons shares used          3,059          3,059          2,907          2,907
                                           ============   ============   ============   ============


    Basic and Diluted Income per share:

    The adjustments in net sales and cost of sales resulted in a net decrease in
    net income available to stockholders of approximately $311,000 and
    $2,022,000 over the amounts previously reported for the three and nine
    months ended September 30, 2002, respectively. Restated basic and diluted
    income per share decreased $0.10 and $0.70, respectively, for the three and
    nine months ended September 30, 2002.

3.  Principles of Consolidation and Accounting Policies

    The consolidated financial statements include the accounts of the Company
    and its subsidiaries. All significant intercompany accounts and transactions
    have been eliminated in consolidation.

    Reclassifications

    Certain reclassifications were made to the prior year financial statements
    to conform to the current year presentation.

    Estimates

    The preparation of financial statements in conformity with accounting
    principles generally accepted in the USA requires management to make
    estimates and assumptions that affect the reported amounts of assets and
    liabilities and disclosure of contingent assets and liabilities at the date
    of the financial statements and the reported amounts of revenues and
    expenses during the reporting period. Actual results could differ from those
    estimates.

                                       8


    Revenue Recognition

    The Company's revenues are primarily derived from sales of products, sales
    of starter and renewal administrative enrollment packs and shipping fees.
    Substantially all product sales are sales to associates at published
    wholesale prices. The Company defers a portion of its revenue from the sale
    of its starter and renewal packs related to its administrative enrollment
    fee. The Company amortizes its deferred revenue and its associated direct
    costs over twelve months, the term of the membership. Total deferred revenue
    for the Company was approximately $2.0 million as of September 30, 2003.

    The Company also estimates and records a sales return reserve for possible
    sales refunds based on historical experience.

    Shipping and Handling Costs

    The Company records freight and shipping revenues collected from associates
    as revenue. The Company records shipping and handling costs associated with
    shipping products to its associates as cost of goods sold.

    Earnings Per Share

    Basic earnings per share is computed based on the weighted average number of
    common shares outstanding during the periods presented. Diluted earnings per
    share data gives effect to all potentially dilutive common shares that were
    outstanding during the periods presented.

4.  Recent Accounting Pronouncements

    FASB Interpretation No. 45. In November 2002, the FASB issued FASB
    Interpretation No. 45, "Guarantor's accounting and Disclosure Requirements
    for Guarantees, Including Indirect Guarantees of Indebtedness of Others"
    (FIN 45). FIN 45 requires that upon issuance of a guarantee, a guarantor
    must recognize a liability for the fair value of an obligation assumed under
    a guarantee. FIN 45 also requires additional disclosures by a guarantor in
    its interim and annual financial statements about the obligations associated
    with guarantees issued. The recognition provisions of FIN 45 are effective
    for any guarantees issued or modified after December 31, 2002. The
    disclosure requirements are effective for financial statements of interim or
    annual periods ending after December 15, 2002. The adoption of FIN 45 did
    not have a material effect on the Company's financial position, results of
    operations, or cash flows.

    FASB Interpretation No. 46. In January 2003, the FASB issued Interpretation
    No. 46, "Consolidation of Variable Interest Entities." Interpretation 46
    changes the criteria by which one company includes another entity in its
    consolidated financial statements. Previously, the criteria were based on
    control through voting interest. Interpretation 46 requires a variable
    interest entity to be consolidated by a company if that company is subject
    to a majority of the risk of loss from the variable interest entity's
    activities or entitled to receive a majority of the entity's residual
    returns or both. A company that consolidates a variable interest entity is
    called the primary beneficiary of that entity. The consolidation
    requirements of Interpretation 46 apply immediately to variable interest
    entities created after January 31, 2003. The consolidation requirements
    apply to older entities in the first fiscal year or interim period beginning
    after December 31 2003. The adoption of this statement did not have a
    material impact to the Company's financial position or results of
    operations.

    SFAS 149. In April 2003, FASB issued Statements of Financial Accounting
    Standards No. 149 ("SFAS 149"), "Amendment of Statement 133 on Derivative
    Instruments and Hedging Activities." SFAS 149 amends SFAS 133 "Accounting
    for Derivatives Instruments and Hedging Activities" and the related
    implementation guidance and is effective for contracts entered into or
    modified after June 30, 2003, except for hedging relationships designated
    after June 30, 2003. SFAS 149 clarifies the definition of a derivative and
    amends the financial accounting and reporting required for derivative
    instruments, including certain derivative instruments embedded in other
    contracts and for hedging activities. In addition, SFAS 149 improves the
    financial reporting requirements by requiring a more consistent reporting of
    contracts as either derivatives or hybrid instruments. The adoption of this
    standard did not have a significant impact on the Company's financial
    condition, results of operations, or cash flows.

                                       9


    SFAS 150. In May 2003, FASB issued Statement of Financial Accounting
    Standards No. 150 ("SFAS 150"), "Accounting for Certain Financial
    Instruments with Characteristics of both Liabilities and Equity." SFAS 150
    broadens the definition of financial instruments and establishes standards
    for how an issuer classifies and measures certain financial instruments with
    characteristics of both liabilities and equity. SFAS 150 also requires that
    an issuer classify a financial instrument that is within its scope as a
    liability or as an asset. SFAS 150 is effective for financial instruments
    entered into or modified after May 31, 2003, and otherwise effective at the
    beginning of the first interim period beginning after June 15, 2003. SFAS
    150 is to be implemented by reporting the cumulative effect of any change in
    accounting principle at the beginning of the period adopted. The adoption of
    SFAS 150 is not expected to have a significant impact on the Company's
    financial condition, results of operations, or cash flows.

5.  Segment Information

    The Company operates in a single reportable operating segment by selling
    products to a global network of independent distributors who operate in a
    seamless manner from market to market. The Company's largest expense is the
    commissions paid on product sales through this distributor network. The
    Company manages its business primarily by managing this global distributor
    network. However, the Company does recognize revenue from sales to
    distributors in thirty countries. The Company's chief operating decision
    makers review both geographic and product line information. The Company has
    operations throughout the world (30 countries as of September 30, 2003) and
    is organized and managed by geographic areas. Information reviewed by the
    Company's chief operating decision makers on significant geographic
    segments, as defined under SFAS 131, is prepared on the same basis as the
    consolidated financial statements.

6.  Equity Transactions

    In January 2003, the Company issued 18,500 shares of Common Stock to a law
    firm for legal services of approximately $34,000.

    In January 2003, the Company issued 10,000 shares of Common Stock to a
    consulting firm for consulting services of approximately $19,000.

    On January 31, 2003, the Company entered into a Database Purchase Agreement
    with NuEworld.com Commerce, Inc. ("NuEworld") and Lighthouse Marketing
    Corporation, our wholly-owned subsidiary ("Lighthouse"), pursuant to which
    Lighthouse purchased a database of associates from NuEworld in exchange for
    the issuance of 360,000 shares of our Common Stock. NuEworld was in the
    business of marketing and selling a variety of products and services through
    its direct-selling distribution network.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

The following discussions should be read in conjunction with the consolidated
financial statements and notes contained in Item 1 hereof.

         Forward Looking Statements

         When used in Form 10-QSB and in future filings by the Company with the
         Securities and Exchange Commission, the words "will likely result",
         "the Company expects", "will continue", "is anticipated", "estimated",
         "projected", "outlook" or similar expressions are intended to identify
         "forward looking statements" within the meaning of the Private
         Securities Litigation Act of 1995. The Company wishes to caution
         readers not to place undue reliance on such forward-looking statements,
         each of which speak only as of the date made. Such statements are
         subject to certain risks and uncertainties that could cause actual
         results to differ materially from historical earnings and those
         presently anticipated or projected. The Company has no obligation to
         publicly release the results of any revisions, which may be made to any
         forward-looking statements to reflect anticipated or unanticipated
         events or circumstances occurring after the date of such statements.

                                       10


Overview

Natural Health Trends Corp. was incorporated on December 1, 1988, in the state
of Florida. NHTC is an international direct-selling company, currently operating
in more than 30 markets throughout Asia, North America and Eastern Europe.

The Company markets premium quality personal care products under the Lexxus
brand and markets its nutritional supplement products under the Kaire brand.
NHTC's common stock, par value $0.001 per share (the "Common Stock"), is listed
on the OTC Bulletin Board (the "OTCBB"). In March 2003, we effected a 1-for-100
reverse stock split with respect to our outstanding shares of Common Stock. In
addition, the trading symbol for the shares of our Common Stock changed from
"NHTC" to "NHLC".

NHTC is a holding company that operates two businesses, Lexxus and eKaire, which
distribute products that promote health, wellness and vitality through two
distinct multi-level marketing ("MLM") channels. The following paragraphs will
outline the progression of NHTC as it is organized today.

In February 1999, NHTC Holdings Inc. acquired certain assets (the "Kaire
Assets") of Kaire International, Inc., a Delaware corporation ("KII"). The
assets included, but not limited to, the corporate name, all variations and any
other product names, registered and unregistered trademarks, tradenames,
servicemarks, patents, logos and copyrights of KII, and independent associate
lists.

In January 2001, NHTC entered into a joint venture with Lexxus International and
formed a new majority-owned subsidiary, Lexxus International, Inc., a Delaware
corporation. The original founders of Lexxus International received an aggregate
of 100,000 shares of our Common Stock and own 49% of the total number of shares
of capital stock of Lexxus International, Inc.

In the second quarter of 2001, we incorporated Lexxus International (SW Pacific)
Pty. Ltd., an Australian corporation and our majority-owned subsidiary, which
does business in Australia ("Lexxus Australia"). In addition, we incorporated
Lexxus International (New Zealand) Limited, a New Zealand corporation and
majority-owned subsidiary of NHTC, which does business in New Zealand ("Lexxus
New Zealand").

In June 2001, we incorporated Lighthouse Marketing Corporation ("Lighthouse"), a
Delaware Corporation and our wholly-owned subsidiary. As of January 31, 2003,
Lighthouse acquired certain assets from NuEworld. See Footnote 6 for more
detail.

In June 2001, we sold all of the outstanding Common Stock in Kaire
Nutraceuticals, Inc., a Delaware corporation, to a South African firm.

In November 2001, we incorporated Lexxus International Co., Ltd., a corporation
organized under the laws of the Republic of China and our majority-owned
subsidiary ("Lexxus Taiwan") which does business in Taiwan.

In January 2002, we incorporated MyLexxus Europe AG, a corporation organized
under the laws of Switzerland and our majority-owned subsidiary ("MyLexxus
Europe"). This company manages the sales of product into sixteen eastern
European countries, including Russia.

In March 2002, we incorporated Lexxus International Co., Ltd., a corporation
organized under the laws of Hong Kong and our wholly-owned subsidiary ("Lexxus
Hong Kong") which does business in Hong Kong.

In April 2002, we incorporated Personal Care International India Pvt. Ltd., a
corporation organized under the laws of India and our wholly-owned subsidiary
("MyLexxus India") which does business in India.

In June 2002, we incorporated Lexxus International Marketing Ltd., a corporation
organized under the laws of Singapore and our majority-owned subsidiary ("Lexxus
Singapore"), which does business in Singapore.

In November 2002, we incorporated Lexxus International (Philippines) Inc., a
corporation organized under the laws of the Philippines and our majority-owned
subsidiary ("Lexxus Philippines"), which does business in the Philippines.

In June 2003, we incorporated LXK Ltd. (South Korea), a corporation organized
under the laws of South Korea and our wholly-owned subsidiary ("Lexxus Korea"),
which does business in South Korea.

                                       11


Results of Operations - Nine Months Ended September 30, 2003 Compared To
The Nine Months Ended September 30, 2002.

As discussed in Note 2 to the consolidated financial statements, we have
restated our results for the three and nine-month periods ended September 30,
2002. All of the following analyses apply the basis of the restated amounts.

Net Sales. Revenues were approximately $39,964,000 and $24,556,000 for the nine
months ended September 30, 2003 and September 30, 2002, respectively, an
increase of $15,408,000 or 63%. The increased sales were primarily from
additional sales of Lexxus products, new distributors and the expansion of
Lexxus into new international markets, including South Korea in June 2003. In
addition, revenues increased due to the deferral of revenue related to the
administrative enrollment fee of distributors, partially offset by a reserve
related to sales returns and refunds and a slight decrease in the sales of
eKaire products.

Cost of Sales. Cost of sales for the nine months ended September 30, 2003 was
approximately $7,450,000 or 19% of net sales. Cost of sales for the nine months
ended September 30, 2002 was approximately $4,415,000 or 18% of net sales. The
total cost of sales increased due to increased sales volume and increased costs
associated with the packaging of the Lexxus product line partially offset by the
deferral of the cost of sales related to the direct cost of the administrative
enrollment fee of the distributors.

Gross Profit. Gross profit increased from approximately $20,140,000 in the nine
months ended September 30, 2002 to approximately $32,514,000 in the nine months
ended September 30, 2003, or an increase of 61%. The increase in gross profit of
approximately $12,374,000 was attributable to higher sales volumes by Lexxus and
also attributable to the deferral of both revenue and cost of sales related to
the administrative enrollment fee of distributors.

Associate Commissions. Associate commissions were approximately $16,498,000 or
41% of sales in the nine months ended September 30, 2003 compared to
approximately $12,413,000 or 51% of sales for the nine months ended September
30, 2002. The increase of commission expense is directly related to the increase
in gross sales and the terms of the Company's compensation plans. The decrease
in commission expense as a percentage of sales is due to the normal fluctuations
that occur in the compensation plan and as well as the amount of revenues
allocatable to the compensation plan.

Selling, General and Administrative Expenses. Selling, general and
administrative expenses increased from approximately $7,216,000 or 29% of sales
in the nine months ended September 30, 2002 to approximately $10,983,000 or 27%
of sales in the nine months ended September 30, 2003. These costs as a
percentage of net sales decreased primarily due to the change in the revenue
amounts with effect to the restatement for the administrative enrollment fee of
the distributors partially offset by general and administrative costs, such as
hiring staff, leasing office space and initial marketing efforts for expansion
into new international markets.

Operating income and net income. Operating income increased from an operating
income of approximately $511,000 for the nine months ended September 30, 2002 to
operating income of approximately $5,033,000 for the nine months ended September
30, 2003. Net income was approximately $3,596,000 for the nine months ended
September 30, 2003 as compared to approximately $267,000 for the nine months
ended September 30, 2002. The increase in net income was due to increased sales
and efficient cost containment efforts partially offset by a provision for
income taxes.

Liquidity and Capital Resources

The Company has historically met its working capital and capital expenditure
requirements, including funding for expansion of operations, through net cash
flows provided by operating activities and through sale of preferred stock. The
Company's principal source of liquidity is its operating cash flows. A
substantial decrease in sales of the Company's products would reduce the
availability of funds.

At September 30, 2003, the ratio of current assets to current liabilities was
1.19 to 1.0 and the Company had working capital of approximately $1,782,000.

                                       12


Cash provided by operations for the nine months ended September 30, 2003 was
approximately $1,908,000 primarily due from increased sales, the launch of the
Company's South Korean operations which were partially offset by increased
accounts receivable, inventory and income tax payable and the reduction of
accounts payable.

Cash used in investing activities for the nine months ended September 30, 2003
was approximately $1,464,000 due to the purchase of an associate database,
increased capital expenditures and an increase in restricted cash. Restricted
cash represents the reserves required by the Company's credit card processor.

Cash used in financing activities for the nine months ended September 30, 2003
was approximately $279,000. Total cash increased by approximately $222,000
during the period.

CRITICAL ACCOUNTING POLICIES

Management's discussion and analysis of our financial condition and results of
operations is based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted in the USA.
The preparation of financial statements requires management to make estimates
and judgments that affect the reported amounts of assets and liabilities,
revenue and expenses and disclosures at the date of the financial statements. We
evaluate our estimates on an on-going basis, including those related to revenue
recognition, legal contingencies and income taxes. We use authoritative
pronouncements, historical experience and other assumptions as the basis for
making estimates. Actual results could differ from those estimates.

SEASONALITY

In addition to general economic factors, we are impacted by seasonal factors and
trends such as major cultural events and vacation patterns. For example, most
Asian markets celebrate their respective local New Year in the first quarter,
which generally has a negative impact on that quarter. We believe that direct
selling in the United States and Europe is also generally negatively impacted
during the month of August, which is in our third quarter, when many
individuals, including our distributors, traditionally take vacations.

CURRENCY RISK AND EXCHANGE RATE INFORMATION

Some of our revenue and some of our expenses are recognized outside of the
United States, except for inventory purchases which are primarily transacted in
U.S. dollars from vendors in the United States. The local currency of each of
our subsidiary's primary markets is considered the functional currency. Revenue
and expenses are translated at the weighted average exchange rates for the
periods reported. Therefore, our reported revenue and earnings will be
positively impacted by a weakening of the U.S. dollar and will be negatively
impacted by a strengthening of the U.S. dollar. Given the uncertainty of
exchange rate fluctuations, we cannot estimate the effect of these fluctuations
on our future business, product pricing, results of operations or financial
condition.

ITEM 3. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our Exchange Act reports is recorded,
processed, summarized and reported within the time periods specified in the
Securities and Exchange Commission's rules and forms and that such information
is accumulated and communicated to our management, including our President and
Chief Financial Officer, as appropriate, to allow for timely decisions regarding
required disclosure. In designing and evaluating the disclosure controls and
procedures, management recognizes that any controls and procedures, no matter
how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management is required to apply
its judgment in evaluating the cost-benefit relationship of possible controls
and procedures.

During the quarter ended September 30, 2003, the Company identified certain
matters that resulted in the restatement of the Company's financial statements
for the three and nine months ended September 30, 2002, as set forth in Note 2
to the Consolidated Financial Statements. Consistent with the foregoing, the
Company intends to restate in the near future the remaining affected periods,
including all quarters in 2001 and 2002 and the first and second quarters of
2003 as well as it's Forms 10-KSB for the years ended December 31, 2001 and
2002.

                                       13


The restatement was the result of misinterpretations of certain accounting
standards and related guidance pertaining to a) revenue recognition of
administrative enrollment fees, b) reserves for returns and refunds, c) a gain
on sale of a subsidiary, and d) income tax provisions. Management together with
the Audit Committee have identified certain improvements that they believe will
result in continuing enhancements to the Company's accounting and reporting
functions and their implementation is ongoing at this time.

Within ninety (90) days prior to the date of this report, the Company's
President and Chief Financial Officer evaluated the effectiveness of the
Company's disclosure controls and procedures. Based upon his evaluation and as a
result, in part, of the matters noted above, the Company's President and Chief
Financial Officer has concluded that the Company's disclosure controls and
procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities
Exchange Act of 1937, as amended) are effective, with the qualification that the
restatements mentioned above were just recently identified and implemented for
the three and nine months ended September 30, 2002. Management requires
additional time to fully (i) assess their correction plan and (ii) implement
appropriate enhancements to its controls and procedures, if and so warranted in
the circumstances.

Since the date of his evaluation, there have been no significant changes to the
Company's internal controls or other factors that could significantly affect
these controls.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

On April 10, 2003, Bobby R. Porter and wife, Betty R. Porter, filed suit against
Lexxus International, Inc. (a majority-owned subsidiary) and Alex Arnold (an
employee of Lexxus International, Inc.) in the 170th District Court of McLennan
County, Texas alleging misrepresentations made by the former owners of
NuEworld.com Commerce, Inc. ("NuEworld") pertaining to a stock investment made
by the plaintiffs in June 2000. The plaintiffs are seeking the sum of $40,000,
court costs and other relief. As disclosed in Note 6, the Company acquired
certain assets of NuEworld in January 2003. The Company filed a motion to
transfer venue in April 2003 and intends to vigorously defend itself in this
case.

The Company is subject to claims and assessments from time to time in the
ordinary course of business. Management does not believe that any such matters,
individually or in the aggregate, will have a material adverse effect on the
Company's financial condition, results of operations or cashflows.

Item 2.  Changes in Securities and Use of Proceeds

In March 2003, NHTC issued 360,000 shares of our Common Stock to NuEworld.com
Commerce, Inc. pursuant to a database purchase agreement.

In January 2003, the Company issued 18,500 shares of Common Stock to a law firm
for legal services of approximately $34,000.

In January 2003, the Company issued 10,000 shares of Common Stock to a
consulting firm for consulting services of approximately $19,000.

Item 3.  Defaults Upon Senior Securities

         Not applicable.

Item 4.  Submission of Matters to a Vote of Security Holders

         Not applicable.

Item 5.  Other Information

         Not applicable.

                                       14


Item 6.  Exhibits and Reports on Form 8-K

         (a)  Exhibits

              31.1 Certification of the President and Chief Financial Officer
              pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

              32.1 Certification of the President and Chief Financial Officer
              pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

         (b)  Reports on Form 8-K
              None.

                                       14


                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                            NATURAL HEALTH TRENDS CORP.

                                            By: /s/ MARK D. WOODBURN
                                                -----------------------------
                                                Mark D. Woodburn
                                                President and Chief
                                                Financial Officer

Date:   April 12, 2004

                                       15